HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

KIDS

OrthoPediatrics Corp. (NASDAQ)

Healthcare — Medical Devices

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

None 9 analysts
$19.30
+$0.17 (+0.89%)
Target: $24.67 (27.8%)
Sign in to add KIDS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$495.72M
P/E Ratio (TTM)-
Forward P/E-28.38
EPS (TTM)$-1.68
Dividend Yield-
Profit Margin-16.31%
Revenue Growth13.30%
ROE-11.57%
Debt/Equity33.13
Recommendation None
Analyst Target$24.67
Analysts9
Indexes NASDAQ

Technical Indicators

RSI (14)56.4
Beta1.02
SMA 20-
SMA 40-
52-Week High$23.70
52-Week Low$14.42
50-Day Avg$17.65
200-Day Avg$17.56
Avg Volume163.3K
Volume160.2K

Performance Analysis

BULLISH

KIDS shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 53% of its 52-week range.
+ RSI at 56.4 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 13.3% year-over-year.
- Operating at a loss with -16.3% margin.
~ Wall Street consensus is "none" from 9 analysts.
+ Average analyst target of $24.67 implies 27.8% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:17 UTC

Back to Screener Export Report